Methods of analyzing nucleic acid fragments

Abstract

Provided herein are methods for enriching a biological sample for a target nucleic acid, and analyzing the nucleic acid. In some cases, a biological sample is enriched for target nucleic acids associated with a cancer or tumor. In some cases, a biological sample is enriched for target nucleic acids, and the target nucleic acids vary in length. In some cases, one or more probes are used to enrich the biological sample for the target nucleic acid. In some cases, one or more probes hybridize to one or more ends of a target nucleic acid.

1 .- 24 . (canceled) 
     
     
         25 . A method for identifying a nucleic acid fragmentation pattern in a subject, comprising:
 (a) enriching, in a biological sample from the subject, for a set of cell-free DNA fragments having ends that are mappable to one or more loci associated with a disease, wherein the enriching comprises hybridizing at least one probe to both a 5′ end and a 3′ end of each of the cell-free DNA fragments, wherein a first sequence along a 3′ end of the at least one probe is complementary to a first target sequence comprising a 3′ most nucleotide of the cell-free DNA fragment, or a second sequence along a 5′ end of the at least one probe is complementary to a second target sequence comprising a 5′ most nucleotide of the cell-free DNA fragment;   (b) subjecting the set of cell-free DNA fragments enriched in (a) to sequencing to obtain a plurality of sequences;   (c) aligning the plurality of sequences to a reference genome to determine genomic positions for the plurality of sequences, the genomic positions including positions corresponding to the ends of the cell-free DNA fragments; and   (d) identifying a set of loci with specific fragmentation patterns in the plurality of sequences, wherein the set of loci correspond to the one or more loci associated with the disease.   
     
     
         26 . The method of  claim 25 , wherein sequencing the set of cell-free DNA fragments does not comprise a step of DNA amplification of the cell-free DNA fragments enriched in (a). 
     
     
         27 . The method of  claim 25 , wherein the identifying the set of loci with specific fragmentation comprises comparing the plurality of sequences to the reference genome to identify the set of loci with specific fragmentation patterns. 
     
     
         28 . The method of  claim 25 , wherein at each locus of the set of loci, a number of sequences having a sequence variant relative to the reference genome is above a threshold. 
     
     
         29 . The method of  claim 25 , wherein the disease is a tumor. 
     
     
         30 . The method of  claim 25 , wherein the plurality of sequences is a plurality of sequence reads. 
     
     
         31 . A method for identifying a nucleic acid fragmentation pattern in a subject, comprising:
 (a) enriching by probe capture, in a biological sample from the subject, for a set of cell-free DNA fragments having ends that are mappable to one or more loci associated with a disease, wherein the enriching comprises hybridizing at least one probe to each end both a 5′ end and a 3′ end of each of the cell-free DNA fragments having ends that are mappable to one or more loci associated with a disease, wherein a first sequence along a 3′ end of the at least one probe is complementary to a first target sequence comprising a 3′ most nucleotide of the cell-free DNA fragment, or a second sequence along a 5′ end of the at least one probe is complementary to a second target sequence comprising a 5′ most nucleotide of the cell-free DNA fragment; and   (b) identifying a set of loci with specific fragmentation patterns in the set of cell-free DNA fragments enriched in (a).   
     
     
         32 . The method of  claim 31 , wherein the set of loci is identified by array hybridization. 
     
     
         33 . The method of  claim 31 , wherein the set of loci is identified by nucleic acid amplification. 
     
     
         34 . The method of  claim 33 , wherein the nucleic acid amplification includes polymerase chain reaction (PCR). 
     
     
         35 . The method of  claim 31 , wherein the disease is cancer. 
     
     
         36 . A method for analyzing cell-free nucleic acid molecules in a biological sample from the subject, the method comprising:
 (a) enriching by probe capture, in the biological sample, for a set of cell-free nucleic acid fragments having ends that are mappable to one or more loci associated with a disease, wherein the enriching comprises hybridizing a probe to both a 5′ end and a 3′ end of each of the cell-free nucleic acid fragments having ends that are mappable to one or more loci associated with a disease, wherein a first sequence along a 3′ end of the at least one probe is complementary to a first target sequence comprising a 3′ most nucleotide of the cell-free nucleic acid fragment, or a second sequence along a 5′ end of the at least one probe is complementary to a second target sequence comprising a 5′ most nucleotide of the cell-free nucleic acid fragment, and wherein the first sequence and the second sequence are separated by a third sequence in the probe;   (b) for each of the cell-free nucleic acid fragments having ends that are mappable to one or more loci, connecting the 3′ end of the cell-free nucleic acid fragment to the 5′ end of the cell-free nucleic acid fragment, thereby forming a circularized cell-free nucleic acid molecule comprising a sequence corresponding to the third sequence; and   (c) determining an amount of the circularized cell-free nucleic acid molecules formed in (b).   
     
     
         37 . The method of  claim 36 , wherein at least two of the set of cell-free nucleic acid molecules fragments are of different lengths. 
     
     
         38 . The method of  claim 36 , wherein the connecting comprises extending the 3′ end of the cell-free nucleic acid fragment to the 5′ end of the cell-free nucleic acid molecule fragment. 
     
     
         39 . The method of  claim 36 , wherein the connecting comprises ligation performed using a ligase. 
     
     
         40 . The method of  claim 36 , further comprising amplifying the circularized cell-free nucleic acid molecules. 
     
     
         41 . The method of  claim 40 , wherein the amplifying comprises performing rolling-circle amplification. 
     
     
         42 . The method of  claim 36 , wherein the determining comprises performing quantitative polymerase chain reaction (PCR). 
     
     
         43 . The method of  claim 36 , wherein the disease is cancer.